James E. Flynn, Director, 10% Owner at Larimar Therapeutics, Inc. (LRMR), bought 5,000,000 shares at $5.00 ($25.0M) on 2026-02-27, disclosed to the SEC on 2026-03-02.
Director James E. Flynn purchased $5.42 million worth of shares at $5.00, marking the largest insider purchase in the company's history. This significant accumulation follows a 67.63% surge over the last 90 days, potentially signaling confidence in the company's recent FDA breakthrough designation.
The stock is currently trading at $5.23, up 67.63% over the last 90 days and 86.12% over the past five days, though it remains 18.54% below its 52-week high of $6.42.
The company reported a Q4 loss of $62.5 million, and the forward P/E is negative at -2.83, indicating ongoing financial losses despite the stock's rally.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.00 | 831,978 | $4.2M | 16.6% |
| 2 | $5.00 | 1,084,010 | $5.4M | 21.7% |
| 3 | $5.00 | 1,084,012 | $5.4M | 21.7% |
| 4 | $5.00 | 2,000,000 | $10.0M | 40.0% |
| Total | $5.00 avg | 5,000,000 | $25.0M | 100% |
| Filing → |
| ONCR | SELL | 2022-12-30 | $65K | — | Filing → |
| ONCR | SELL | 2022-12-21 | $23K | — | Filing → |
| AFIB | BUY | 2021-07-21 | $15.0M | — | Filing → |